StockData

Acadia Pharmaceuticals vs TG Therapeutics

ACAD and TGTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ACAD and TGTX compare

TG Therapeutics is the larger company, worth 3.0 times as much as Acadia Pharmaceuticals ($9.6B against $3.2B).

On earnings, Acadia Pharmaceuticals is cheaper: it trades at 8.3× trailing earnings, against 22.9× for TG Therapeutics.

TG Therapeutics grew revenue faster over the last twelve months (76.1% versus 11.8% for Acadia Pharmaceuticals).

TG Therapeutics keeps more of each dollar of sales as profit, with a net margin of 55.2% compared with 33.4% at Acadia Pharmaceuticals.

Acadia Pharmaceuticals scores higher on the StockData Score (16 against 9 for TG Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricACADTGTX
Size and price
Market cap$3.2B$9.6B
Share price$18.32$62.71
Change, 1 year−23.7%102%
Change, 5 years−2.5%162%
Beta (5Y)0.530.47
Employees798399
StockData Score
Total score16 (better)9
Valuation score4 (better)1
Growth score22
Performance score44
Health score6 (better)2
Dividend score00
Valuation
P/E8.3× (better)22.9×
P/S2.8× (better)12.0×
P/B2.4× (better)15.9×
EV/EBITDA25.5× (better)71.3×
P/FCF21.7× (better)552×
FCF yield4.6% (better)0.18%
Fair value$25.26$60.66
Margin of safety27.5% (better)−3.4%
Growth
Revenue growth (TTM)11.8%76.1% (better)
Revenue growth, 5Y average19.4%427% (better)
Net income growth (TTM)71.3%630% (better)
EPS growth (TTM)66.2%641% (better)
Profitability
Gross margin91.1% (better)82.4%
Operating margin7.6%17.1% (better)
Net margin33.4%55.2% (better)
FCF margin12.8% (better)2.2%
Return on equity35.7%100% (better)
Return on invested capital42.1% (better)27.8%
Financial health
Debt / equity0.001.23 (better)
Net debt / EBITDA–0.98
Interest coverage–3.6×
Current ratio3.394.27 (better)
Altman Z-score4.326.07 (better)
Piotroski F-score6 (better)4
Dividends and buybacks
Buyback yield−1.5%1.9% (better)
Shareholder yield−1.5%1.9% (better)
Ownership
Held by institutions97.9%72.6%
Held by insiders27.8%16.1%
Insider net buying, 12 months−$2.5M−$275K (better)
Short interest, % of float6.7%22.4%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.